Treatment using Fms-like tyrosine kinase-3 (FLT3) inhibitors is a promising approach to overcome the dismal prognosis of acute myeloid leukemia (AML) with activating FLT3 mutations. Current trials are combining FLT3 inhibitors with p53-activating conventional chemotherapy. The mechanisms of cytotoxicity of FLT3 inhibitors are poorly understood. We investigated the interaction of FLT3 and p53 pathways after their simultaneous blockade using the selective FLT3 inhibitor FI-700 and the MDM2 inhibitor Nutlin-3 in AML. We found that FI-700 immediately reduced antiapoptotic Mcl-1 levels and enhanced Nutlininduced p53-mediated mitochondrial apoptosis in FLT3/internal tandem duplication cells through the Mcl-1/Noxa axis. FI-700 induced proteasome-mediated degradation of Mcl-1, resulting in the reduced ability of Mcl-1 to sequester proapoptotic Bim. Nutlin-3 induced Noxa, which displaced Bim from Mcl-1. The FI-700/Nutlin-3 combination profoundly activated Bax and induced apoptosis. Our findings suggest that FI-700 actively enhances p53 signaling toward mitochondrial apoptosis and that a combination strategy aimed at inhibiting FLT3 and activating p53 signaling could potentially be effective in AML.
Introduction
Activating mutations of the Fms-like tyrosine kinase-3 gene (FLT3) occur in approximately 30-40% of acute myeloid leukemia (AML) patients. [1] [2] [3] FLT3 mutations consist of two major types: internal tandem duplication (ITD) mutations of 3-400 bp (always in frame) that map to the juxtamembrane region (20-25% of AML patients) and kinase domain (KD) point mutations in codons 835 and 836 (B7% of AML patients). FLT3 mutations have been reported to be associated with poor prognosis. 4, 5 Unlike the wild-type (WT) counterpart, FLT3 mutations confer numerous oncogenic properties, including dysregulated proliferation, resistance to apoptosis and a block in differentiation. 6 FLT3 mutations result in constitutive activation of the FLT3 receptor kinase in the absence of its ligand (FLT3 ligand) and abnormal activation of the downstream pathways, including signal transducer and activator of transcription 5 (STAT5), mitogen-activated protein kinase kinase (Mek)/extracellular signal-regulated kinase (Erk) and phosphatidylinositol-3 kinase (PI3K)/Akt. 7, 8 Activation of these downstream effectors has been thought to allow leukemia cells to evade apoptosis.
Bcl-2 family proteins execute apoptosis and the balance between proapoptotic Bcl-2 family members and antiapoptotic members dictates the fate of a cell following an apoptotic stimulus. Many Bcl-2 family members, including both proapoptotic (for example, Bad) and antiapoptotic (for example, Bcl-2, Bcl-X L and Mcl-1) species, are regulated by STAT5, PI3K/Akt and Mek/Erk pathways. [9] [10] [11] For example, activation of Mek/Erk and PI3K/Akt pathways results in Bad phosphorylation 9, 10 and STAT5 activation upregulates the expression of Bcl-X L , 10 both of which promote cell survival. Mcl-1 is an antiapoptotic Bcl-2 family protein, which has a critical pro-survival role in the development and maintenance of both normal and malignant tissues. 11 Unlike other antiapoptotic Bcl-2 proteins, Mcl-1 is acutely regulated with a half-life of approximately 30 min and contains two PEST sequences that are typically present in short-lived proteins. Expression of Mcl-1 is upregulated at the transcriptional level by STAT5, PI3K/Akt and Mek/Erk pathways [11] [12] [13] and at the posttranslational level by the PI3K/ Akt pathway. 14 It has been reported that FLT3 inhibition induces apoptosis in leukemic blasts of AML patients who carry the FLT3 mutation, [15] [16] [17] [18] [19] [20] [21] though the mechanism remains unknown. Several FLT3 inhibitors have been developed, including sorafenib (BAY43-9006), lestaurtinib (CEP-701), PKC412, sunitinib (SU11248) and tandutinib (MLN-518), but clinical trials using these inhibitors as single agents have not been successful. [17] [18] [19] [20] [21] Conventional chemotherapy in combination with FLT3 inhibitors has therefore emerged as the preferred therapeutic strategy in the current phase 3 trials. [17] [18] [19] It is conceivable that targeting multiple arms of the apoptotic regulatory machinery with FLT3 inhibition would be more efficacious than targeting the mutated FLT3 alone.
p53 is the most frequently inactivated protein in human malignancies and more than 50% of all solid tumors carry mutations in the TP53 gene. 22 In AML, TP53 mutations are rare, however, inactivation of the WT p53 protein frequently occurs through overexpression of its negative regulator MDM2. 23 MDM2 binds p53 at the transactivation domain of p53 and blocks its ability to activate transcription, serves as a ubiquitin ligase that promotes p53 degradation, and furthermore, mediates the nuclear export of p53. 24 We have reported that the potent and selective small-molecule antagonist of MDM2, Nutlin-3, 25 strongly inhibits growth and induces p53-mediated apoptosis in AML. 23 p53 activation results in disruption of the balance of antiapoptotic and proapoptotic Bcl-2 family proteins, which can trigger mitochondrial outer membrane permeabilization and apoptosis through activation of Bax/Bak. 26, 27 BH3-only proapoptotic Noxa is a p53 target that is immediately (B1 h) induced by p53 in AML cells. 23 Here, we report the apoptotic effect of the simultaneous inhibition of mutant FLT3 by FI-700 and activation of p53 signaling by the MDM2 inhibitor Nutlin-3 in AML. FI-700 is a selective inhibitor of mutant FLT3 protein kinase activity. 15 We found that FI-700 immediately reduced antiapoptotic Mcl-1 levels and enhanced Nutlin-induced p53-mediated mitochondrial apoptosis in FLT3/ITD-expressing AML cells through Mcl-1/ Noxa axis. This research suggests that the combined inhibition of FLT3 and MDM2 interferes with an Mcl-1-mediated cross talk between Noxa and Bim, resulting in Bax activation and apoptosis in FLT3/ITD-expressing cells. Thus, FLT3 inhibition, in combination with p53-inducing agents, might represent a potential therapeutic approach in AML with FLT3/ITD.
Materials and methods

Reagents
The selective FLT3 inhibitor FI-700, BH3 mimetic ABT-737 and the selective small-molecule antagonist of MDM2, Nutlin-3 (Axxora, San Diego, CA, USA) were dissolved in dimethyl sulfoxide and kept frozen at À20 1C. In some experiments, cells were cultured with 70 mM cycloheximide, 10 mM MG132 or 100 mM Z-VAD-FMK (Axxora). This solution was added to the cells 1 h before drug administration.
Antibodies
The following antibodies were used: rabbit polyclonal anti-p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse monoclonal anti-p21 (EMD Biosciences, San Diego, CA, USA); mouse monoclonal anti-MDM2 (Santa Cruz Biotechnology); mouse monoclonal anti-Noxa (EMD Biosciences); mouse monoclonal anti-Bcl-2 (DakoCytomation, Carpinteria, CA, USA); mouse monoclonal anti-Bcl-2 (C-2; Santa Cruz Biotechnology); rabbit polyclonal anti-Bcl-X L (BD Transduction Laboratories, Palo Alto, CA, USA); mouse monoclonal anti-Mcl-1 (BD Pharmingen, San Diego, CA, USA); rabbit polyclonal anti-Mcl-1 (Santa Cruz Biotechnology); rabbit polyclonal anti-Bax (Cell Signaling Technology, Beverly, MA, USA); mouse monoclonal anti-Bax (Trevigen, Gaithersburg, MD, USA); mouse monoclonal anti-Bak (EMD Biosciences); mouse monoclonal anti-Bad (Millipore, Billerica, MA, USA); mouse monoclonal antiphospho-Bad (Ser 112 ) (Cell Signaling Technology); rat monoclonal anti-Bim (Axxora); rabbit monoclonal anti-Bim (EMD Biosciences); rabbit polyclonal anti-Puma (EMD Biosciences); rabbit polyclonal anti-FLT3 (Santa Cruz Biotechnology); rabbit monoclonal anti-phospho-FLT3 (Tyr  589/ 28,29 MOLM-13 cells were transduced with lentiviruses encoding either Noxaspecific shRNA (nucleotides 296-317, GenBank accession no. NM021127) or scrambled shRNA, and stable shRNA-expressing cells were generated. The corresponding oligonucleotides were annealed and cloned under the control of the H1 promoter into a self-inactivating lentiviral vector. The vector was also designed to carry the green fluorescent protein reporter gene under control of the human ubiquitin-C promoter to monitor infection efficiency. The potency and specificity of each construct were determined by protein immunoblotting. Heparinized blood or bone marrow samples with more than 60% leukemia cells were obtained from AML patients after informed consent, according to institutional guidelines per the Declaration of Helsinki Principles. Mononuclear cells were purified by Ficoll-Hypaque (Sigma) density-gradient centrifugation, and nonadherent cells were resuspended in RPMI 1640 medium supplemented with 10% FCS at a density of 5 Â 10 5 cell per ml.
Cell-cycle and apoptosis analysis
For cell-cycle analysis, we fixed cells in 70% ice-cold ethanol and stained with propidium iodide (PI) solution (25 mg/ml PI, 180 U/ml RNase, 0.1% Triton X-100 and 30 mg/ml polyethylene glycol in 4 mM citrate buffer (pH 7.8); Sigma Chemical, St Louis, MO, USA). The DNA content was determined using a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). Data were gated on the FL2-area versus FL2-width cytogram to exclude doublets and aggregates; a minimum of 3 Â 10 4 gated cells were analyzed per sample. Cell-cycle distribution was analyzed using ModFit LT software (Verity Software House, Topsham, ME, USA). Cells with hypodiploid DNA content were counted as apoptotic based on DNA fragmentation. For Annexin-V-binding studies, we washed cells twice with binding buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 140 mM NaCl and 5 mM CaCl 2 at pH 7.4; Sigma Chemical) and incubated with a 1:50 solution of FITC (fluorescein isothiocyanate)-conjugated Annexin V (Roche Diagnostic, Indianapolis, IN, USA) or a 1:20 solution of allophycocyaninconjugated Annexin V (BD Pharmingen) for 15 min at room temperature. Stained cells were analyzed by flow cytometry and membrane integrity was simultaneously assessed by PI exclusion. To measure mitochondrial membrane potential (Dc m ), we loaded cells with MitoTracker Red CMXRos (300 nM) and MitoTracker Green (100 mM, both from Molecular Probes, Eugene, OR, USA) for 1 h at 37 1C. The Dc m was then assessed by measuring CMXRos retention (red fluorescence), whereas simultaneously adjusting for mitochondrial mass (green fluorescence). The extent of drug-specific apoptosis was assessed by the formula: % specific apoptosis ¼ (testÀcontrol) Â 100/ (100Àcontrol). In the formula, the numerator is the actual amount of killing that occurred and the denominator is the potential amount of killing that could occur.
Western blot analysis and co-immunoprecipitation
Equal amounts of protein lysate were separated by SDSpolyacrylamide gel electrophoresis (12%) for 2 h at 80 V. Proteins were transferred to Hybond-P membranes (Amersham Biosciences, Piscataway, NJ, USA), immunoblotted with appropriate antibodies and were reacted with enhanced chemiluminescence reagent (Amersham Biosciences). Signals were detected by Light-Capture AE-6981FC (Atto, Tokyo, Japan). An anti-b-actin blot was used in parallel as a loading control. Visualized blots were analyzed by the ImageJ version 1.32 software (National Institutes of Health, Bethesda, MD, USA). For co-immunoprecipitation of Mcl-1, we lysed cells (5 Â 10 6 cells) in buffer (500 ml) containing 150 mM NaCl, 10 mM HEPES (pH 7.4), 1% CHAPS and protease inhibitors. Protein lysates were subjected to immunoprecipitation using anti-Mcl-1 (Santa Cruz Biotechnology) and immunoprecipitates were subjected to western blot analysis with anti-Mcl-1 (BD Pharmingen), Bak (EMD Biosciences), Bim (Axxora) or Noxa (EMD Biosciences). Lysates were also immunoprecipitated with anti-Bim (Axxora) and the immunoprecipitates were immunoblotted with anti-Bim (EMD Biosciences), anti-Mcl-1 (BD Pharmingen) or anti-Bcl-2 (Santa Cruz Biotechnology).
Quantitation of intracellular proteins by flow cytometry
Involvement of Bax conformational change was analyzed by means of an antibody directed against the N-terminal region of Bax (YTH-6A7; Trevigen). Cellular fixation, permeabilization and staining with primary antibody or an isotypic control were performed using the Dako IntraStain kit (DakoCytomation), according to the manufacturer's instructions. After washing, cells were incubated with Alexa Fluor 488 chicken anti-mouse secondary antibodies (Molecular Probes) for 30 min at 4 1C. The extent of drug-specific Bax activation was assessed by the formula: % specific Bax activation ¼ (testÀcontrol) Â 100/ (100Àcontrol). Total Bax levels were determined by using polyclonal anti-Bax antibodies (Cell Signaling Technology) and Alexa Fluor 488 chicken anti-rabbit secondary antibodies (Molecular Probes). Cleaved caspase-3 was labeled with FITCconjugated anti-active caspase-3 antibody (BD Pharmingen).
Detection of FLT3/ITD and codon 835/836 mutations
Genomic DNA was assessed for FLT3 mutations representing either ITDs or point mutations involving codon 835 by polymerase chain reaction (PCR) followed by capillary electrophoretic separation on an Applied Biosystems genetic analyzer (Applied Biosystems, Foster City, CA, USA), as previously reported. 17 Briefly, the forward primers for each site were labeled fluorescently with 6-carboxyfluorescein (FAM). The forward and reverse primers used to assess ITDs were 5 0 -FAM-GCAATTTAGGTATGAAAGCCAGC-3 0 and 5 0 -CTTTCAGCATTT TGACGGCAACC-3 0 , respectively. The forward and reverse primers used to assess point mutations in codon 835 were 5 0 -FAM-CCGCCAGGAACGTGCTTG-3 0 and 5 0 -GCAGCCTCACA TTGCCCC-3 0 , respectively. For detections of mutations within codons 835 and 836, we subsequently digested the PCR products with EcoRV. In the unmutated FLT3 sequence, EcoRV digestion created two fragments, of which the smaller one was detected by the fluorochrome label, in contrast to the large undigested labeled fragment seen with the mutant versions of FLT3. The sensitivity of the FLT3/ITD and codon 835/836 assays was such that they could detect 1% of mutation-bearing cells, as established by the dilution studies that were included in every experiment. For FLT3/ITD direct sequencing the ITD PCR primers were used.
TP53 mutation analysis
Total RNAs were extracted from cells with the RNeasy Mini Kit (Qiagen, Hilden, Germany). First-strand cDNA synthesis was performed with oligo(dT) as primer (Superscript II System; Invitrogen, Carlsbad, CA, USA). PCR for p53 gene expressions followed by direct sequencing were performed as described previously. 23 
Statistical analysis
Statistical analysis was performed using the two-tailed Student's t-test. Results were considered statistically significant at P-values o0.05. Average values were expressed as mean ± s.d. Synergism, additive effects and antagonism were assessed, as previously described. 23 The combination index (CI), a numerical description of combination effects, was calculated using the more stringent statistical assumption of mutually nonexclusive modes of action. When CI ¼ 1, this equation represents the conservation isobologram and indicates additive effects. CI values less than 1.0 indicate a more than expected additive effect (synergism), whereas CI values greater than 1.0 indicate antagonism between the two drugs.
Results
FLT3 inhibition by FI-700 induces G 1 -phase cell-cycle arrest and apoptosis in FLT3/ITD-expressing AML cell lines
We first examined the effect of the FLT3 inhibitor, FI-700, on the growth and viability of cultured AML cell lines. They expressed FLT3 at the protein level (Figure 1a) . FI-700 inhibited phosphorylation of FLT3 with 50% inhibition at 100 nM and 495% inhibition at 800 nM in MOLM-13 cells (Figure 1b 
25 FLT3/ITD-expressing MOLM-13 and FLT3/WT OCI-AML-3 cells have WT p53, whereas FLT3/WT HL-60 cells deleted p53.
23 FLT3/ITD MV4-11NR cells spontaneously developed resistance to Nutlininduced apoptosis upon prolonged passage in tissue culture (Figure 2a) , acquiring a missense mutation (CGG-TGG; R248W) occurred in the DNA-binding domain (Figure 2b ). TP53 R248W mutation has been reported as a somatic mutation in more than 600 cancers and the mutated p53 is transcriptionally inactive.
30 MV4-11NR cells had FLT3/ITD identical to parental MV4-11 cells (data not shown). MOLM-13 and OCI-AML-3 cells were, as previously reported, 23 susceptible to Nutlin-induced apoptosis (Figure 3a) . Conversely, p53 mutant MV4-11NR as well as p53-deleted HL-60 cells was resistant to Nutlin-induced apoptosis, confirming selective inhibition of MDM2 and WT p53 interaction by Nutlin-3. (Figure 3a) . These findings suggest that FI-700 synergizes with Nutlin-3 in inducing apoptosis in FLT3/ITD and p53 WT AML cells.
25
p53-mediated apoptotic pathways converge on the interaction between antiapoptotic and proapoptotic Bcl-2 family proteins, resulting in activation and conformational change of the proapoptotic protein Bax. Involvement of the Bax conformational change was analyzed by means of an antibody directed against the N-terminal region of Bax (clone YTH-6A7), which reacts only with Bax in its active conformation. AML cells were preincubated for 1 h in the presence of 100 mM Z-VAD-FMK before the addition of FI-700, Nutlin-3 or both to inhibit caspase-activation-mediated Bax cleavage. FI-700 induced Bax activation in FLT3/ITD-expressing MOLM-13 and MV4-11NR, whereas Nutlin-3 activated Bax in p53 WT MOLM-13 and OCI-AML-3 (Figure 3b ). FI-700 considerably enhanced Bax conformational change by Nutlin-3 in MOLM-13 (Figure 3b ). No differences in the fluorescence intensity between the control and drug-treated cells were observed when Bax antibodies that detect total Bax were used in these cells (not shown). 31 Nutlin-induced p53 can directly activate Bax 26,27 and results of our study suggest that FLT3 inhibition actively enhances the p53-mediated mitochondrial apoptotic pathway. Synergistic Bax activation by the FI-700/Nutlin-3 combination was evident as early as at 8 h of exposure (Figure 3c ) and, in accordance with the conformational change of Bax, FI-700 synergized with Nutlin-3 to induce Dc m loss and caspase-3 activation in FLT3/ITD and p53 WT MOLM-13 cells (Figure 3c ). To determine if neutralizing antiapoptotic Bcl-2 family proteins could augment apoptosis induced by FLT3 inhibition, we combined FI-700 with the BH3 mimetic ABT-737 in AML cells. ABT-737 targets antiapoptotic Bcl-2 family proteins and causes mitochondrial apoptosis in cells independent of their p53 status. 32 ABT-737 induced phosphatidylserine externalization in all four AML cell lines tested (Figure 3d ). The combination studies showed strong synergism between FI-700 and ABT-737 in inducing apoptosis in MOLM-13 and MV4-11NR cells (Figure 3d) , with the averaged CI values being 0.15 in MOLM-13 and 0.02 in MV4-11NR cells, respectively. This result is consistent with a previous observation. 33 Taken together, our results suggest that mitochondrial apoptotic pathways can be important in cell death induction by the FI-700/Nutlin-3 combination.
FI-700 rapidly downregulates antiapoptotic Mcl-1 through proteasome-dependent degradation in MOLM-13 cells
To investigate the molecular events that contribute to apoptosis induced by FI-700/Nutlin-3 treatment, we treated MOLM-13 cells with 400 nM FI-700 or 2.5 mM Nutlin-3, either as individual agents or in combination; pro-and antiapoptotic protein levels were investigated (Figure 4a ). FI-700 treatment rapidly reduced Mcl-1 levels at 2 h. Levels of the remaining Bcl-2 family proteins did not change significantly. The Mcl-1 reduction after FI-700 treatment appeared to be associated with FLT3 inhibition, as FI-700 reduced Mcl-1 levels exclusively in FLT3/ITD cells (Figure 4b ). As previously reported, 23 Nutlin-3 treatment resulted in increased p53 levels (Figure 4a ). Levels of downstream transcriptional targets of p53, including MDM2, p21 and Noxa, were subsequently increased. Mcl-1 levels were modestly reduced. Antiapoptotic Bcl-2 and Bcl-X L levels and proapoptotic Bax, Bak, Bim and Puma levels remained unchanged 6 h after exposure to Nutlin-3. Proapoptotic Bad levels increased after Nutlin-3 treatment, in correlation with increased levels of its phosphorylated antiapoptotic form. The FI-700/ Nutlin-3 combination profoundly reduced Mcl-1 levels. The concomitant increase of proapoptotic total and antiapoptotic phosphorylated Bad levels was also seen in the FI-700/Nutlin-3 combination, making it unlikely that Bad has a central role in the synergistic apoptosis induction.
Activation of STAT5, PI3K/Akt or Mek/Erk pathways that are downstream of the FLT3 receptor has been shown to upregulate Mcl-1 protein synthesis.
11-14,34 MOLM-13 cells constitutively expressed phosphorylated Erk, Akt and STAT5, and, consistent with rapid reduction of Mcl-1 after FI-700 treatment, FI-700 was effective in blocking their phosphorylation (Figure 4c ). To elucidate how FLT3 inhibition and induction of p53 reduce Mcl-1 levels, we treated MOLM-13 cells with 400 nM FI-700 and 5 mM Nutlin-3 for 2 h, either as individual agents or in combination after 1-h preincubation with 70 mM cycloheximide, 10 mM MG132 or 100 mM Z-VAD-FMK. Cycloheximide affected the rate of decrease in Mcl-1 levels after FI-700 treatment (Figure 4d ), implying that there are mechanism(s) other than blockage of new protein synthesis to reduce Mcl-1. The proteasome inhibitor MG132 blocked Mcl-1 reduction after FI-700 treatment (Figure 4d ), suggesting that FLT3 inhibition enhances proteasome-dependent degradation of Mcl-1. Mcl-1 is a substrate for caspase-mediated degradation. However, the pan-caspase inhibitor Z-VAD-FMK did not block Mcl-1, indicating that the mechanism is independent of caspasemediated degradation. It has been reported that Noxa, a transcriptional target of p53, induces proteasome-dependent degradation of Mcl-1.
35 MG132 also efficiently blocked Mcl-1 reduction after Nutlin-3 and the FI-700/Nutlin-3 combination (Figure 4d ). These data suggest that FLT3 inhibition and p53 induction enhance Mcl-1 degradation by the activity of the proteasome.
FI-700 and Nutlin-3 combination prevents Mcl-1 from sequestering Bim in MOLM-13 cells
Mcl-1 interacts with Bim, Bak and Noxa, whereas Noxa has been found to bind preferentially to Mcl-1.
11 In MOLM-13 cells, immunoprecipitation with anti-Mcl-1 followed by immunoblotting showed a specific Mcl-1/Noxa and Mcl-1/Bim complexes ( Figure 5 ). The association of Mcl-1 with Bak was not detected. 
FI-700 augments p53-mediated apoptosis in FLT3/ITD primary AML cells
We cultured primary cells from 11 AML patients with more than 60% blasts with 400 nM FI-700 and/or 5 mM Nutlin-3 and then evaluated Bax activation and Dc m after 12 and 18 h, respectively. The patient characteristics are summarized in Table 1 . Cells from seven FLT3/WT cases showed a minimal increase in percentages of cells undergoing specific Dc m loss after treatment with FI-700 (3.2 ± 2.6% specific apoptosis), whereas three of four FLT/ITD cases showed more than 10% FI-700-specific apoptosis (Figure 8a ). All 11 samples were sensitive to Nutlininduced apoptosis (Figure 8a) , suggesting a WT p53 status. The relation between the p53 status of cells and apoptotic sensitivity to Nutlins has already been established. 23, 36 The cooperative nature of the FI-700/Nutlin-3 interaction was seen in three FLT3/ITD samples (Figure 8a) . Analysis of involvement of Bax conformational change showed similar results (Figure 8b ). These 
Discussion
Our results suggest that the FLT3 inhibitor FI-700 strongly enhances p53-mediated mitochondrial apoptosis in AML cells. FI-700 treatment enhanced Nutlin-induced phosphatidylserine externalization at 12 h, which is 4 h earlier than phosphatidylserine externalization induced by FI-700 as an individual agent. Furthermore, synergistic Bax activation by the FI-700/Nutlin-3 combination was detected at 8 h when FI-700 alone caused minimal cell-cycle arrest, arguing against the idea that apoptosis induction by FLT3 inhibition is a secondary event in arrested cells at the G 1 phase. These findings suggest that FLT3 inhibition directly induces mitochondrial outer membrane permeabilization in FLT3/ITD AML cells. In this context, we found that FI-700 treatment immediately and profoundly downregulates antiapoptotic Mcl-1 in FLT3/ITD AML cells, although the mechanisms by which FLT3 inhibition targets Mcl-1 for proteasomal degradation are currently unknown and are subject for further studies.
Mcl-1 is an antiapoptotic Bcl-2 family protein and blocks cytochrome c release from mitochondria by interacting with proapoptotic members of the Bcl-2 protein family, thereby preventing Bax/Bak activation and mitochondrial outer membrane permeabilization. The idea that Mcl-1 is a critical therapeutic target in FLT3/ITD AML is supported by the recent paper identifying a molecular mechanism leading to primary clinical resistance to the FLT3 inhibitor PKC412. 37 In that scenario, selection of a drug-resistant leukemic clone with atypical ITD mutation (FLT3_ITD627E) occurs upon start of treatment and the Mcl-1 levels become no longer suppressed by PKC412 treatment.
We propose that the avid binding of Bim and Noxa to Mcl-1 could contribute to the synergistic apoptotic effect of the FI-700/ Nutlin-3 combination. Under nonapoptotic conditions Bim has been found to be sequestered by Mcl-1, which neutralizes its apoptotic activity. 37 In line with our results, it has been demonstrated that Noxa displaces Bim from sequestration by Mcl-1 in a mutually exclusive manner. 38, 39 FI-700 reduces Mcl-1 by proteasome-mediated degradation in FLT3/ITD AML cells, which would result in the reduced ability of Mcl-1 to sequester proapoptotic Bim and facilitate Bim-dependent apoptosis. 40 Nutlin-3 induces p53 in AML cells with WT p53, resulting in increased levels of Noxa. 23 The Noxa-mediated displacement of Bim from Mcl-1 sequestration could represent a molecular mechanism that underlies the cooperation between FI-700 and Nutlin-3. In accordance with this hypothesis, FI-700 showed striking synergistic apoptotic effects with ABT-737. ABT-737 is a promising BH3 mimetic that causes the regression FLT3 inhibition enhances p53-mediated apoptosis K Kojima et al of some tumors in mouse xenograft models. 41 However, its efficacy as a single agent against many cancers is limited because it binds tightly to Bcl-2, Bcl-X L and Bcl-w, but not to Mcl-1. 42, 43 The strategies that target Mcl-1 have been found to sensitize many cell types to ABT-737, 42, 43 which would be applicable to AML with activating FLT3 mutations. 33 Because TP53 mutations are rare in AML, most patients with activating FLT3 mutations can potentially benefit from combination treatment with FLT3 inhibitor and p53-activating agents (for example, Nutlins, anthracyclines, alkylating agents, topoisomerase inhibitors and so on). It has been reported that a proportion of patients harboring FLT3 mutations exhibit primary resistance to FLT3 inhibitor treatment, although the precise mechanisms are largely unknown. 37, 44 In our series, AML cells from one of the FLT3/ITD cases (case 11) showed resistance to FI-700-induced apoptosis. Of particular interest is whether the combined FLT3 inhibition and p53 activation could overcome specific mechanisms of resistance to FLT3 inhibitors.
